Sugi Predict

Sugi Predict / Compounds / SCHEMBL2656359

SCHEMBL2656359

SCHEMBL2656359

O=S(=O)(Oc1cc(O)cc2ccccc12)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.43
▸ KDM4E B2RXH2 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ MAPT P10636 1/20 0.42
▸ MPI P34949 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ CDC25B P30305 3/20 0.40
▸ PTPN1 P18031 1/20 0.37
▸ CYP2D6 P10635 1/20 0.36
▸ HSD17B10 Q99714 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TRPM4 Q8TD43 1/20 0.33
▸ MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30064989 1.00 NQO2 (0.43) NQO2KDM4EALDH1A1MEN1KMT2A
SCHEMBL28211609 0.84 ADORA2A (0.34) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL31722992 0.84 ADORA2A (0.39) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL6937631 0.83 GPR84 (0.45) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL17945537 0.82 KMT2A (0.40) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL19959255 0.82 CYP1A2 (0.43) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL15998741 0.82 HTT (0.39) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL16539802 0.81 TOP2A (0.35) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL7734702 0.81 NQO2 (0.48) NQO2KDM4EALDH1A1MEN1KMT2A
SCHEMBL23668715 0.81 ALOX15 (0.39) MEN1KMT2AHPGDMAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
US-8318760-B2 Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists MERCK SHARP & DOHME CORP. (US) 2012-11-27 — — US disclosed
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-07-03 — — US disclosed
CN-101146762-A Substituted aryl and heteroaryl derivatives MERCK & CO INC (US) 2008-03-19 — — CN disclosed
EP-1863755-A1 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES Merck & Co., Inc. (US) 2007-12-12 — — EP disclosed
WO-2006102067-A1 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES MERCK & CO., INC. (US) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS NQO2 1350/4885KDM4E 2825/4885ALDH1A1 1816/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS NQO2 402/4885KDM4E 3110/4885ALDH1A1 2871/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NQO2 805/4885KDM4E 3689/4885ALDH1A1 3370/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS NQO2 982/4885KDM4E 3843/4885ALDH1A1 1957/4885
US-20080161347-A1 Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use GPR119, PNLIP, SLC5A2 NQO2 603/4885KDM4E 2408/4885ALDH1A1 863/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS NQO2 473/4885KDM4E 3340/4885ALDH1A1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback